source
- Tyra Biosciences reports phase 2 bladder cancer data, complete response rates miss analyst targets, shares slideTyra Biosciences disclosed early phase 2 results for its FGFR3‑selective inhibitor dabogratinib in patients with low‑grade, intermediate‑risk non‑muscle‑invasive bladder cancer. The trial evaluate…
- TwoStep Therapeutics raises $62.5 million Series A backed by Pfizer and Merck KGaA venture groupsTwoStep Therapeutics, a cancer biotech, announced a $62.5 million Series A financing to advance its novel approach to antibody-drug conjugates and radioligand therapies. The round was supported by…Endpoints · 18h agoDealPositive